Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Nephroprotection by SGLT2 Inhibition: Back to the Future?
Luca De Nicola, Francis B. Gabbai, Carlo Garofalo, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 7, pp. 2243-2243
Open Access | Times Cited: 36

Showing 1-25 of 36 citing articles:

An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
Teresa Salvatore, Raffaele Galiero, Alfredo Caturano, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 7, pp. 3651-3651
Open Access | Times Cited: 149
Kidney Fibrosis and Oxidative Stress: From Molecular Pathways to New Pharmacological Opportunities
Francesco Patera, Leonardo Gatticchi, Barbara Cellini, et al.
Biomolecules (2024) Vol. 14, Iss. 1, pp. 137-137
Open Access | Times Cited: 15
Impact of dapagliflozin treatment on renal function and diuretics use in acute heart failure: a pilot study
Kristina Charaya, Dmitry Shchekochikhin, Д. А. Андреев, et al.
Open Heart (2022) Vol. 9, Iss. 1, pp. e001936-e001936
Open Access | Times Cited: 32
Clinical Implications of Estimated Glomerular Filtration Rate Dip Following Sodium‐Glucose Cotransporter‐2 Inhibitor Initiation on Cardiovascular and Kidney Outcomes
Yan Xie, Benjamin Bowe, Andrew K. Gibson, et al.
Journal of the American Heart Association (2021) Vol. 10, Iss. 11
Open Access | Times Cited: 34
Antifibrotic effects of sodium-glucose cotransporter-2 inhibitors: A comprehensive review
Neda Shakour, Shima Karami, Mehrdad Iranshahi, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2023) Vol. 18, Iss. 1, pp. 102934-102934
Closed Access | Times Cited: 12
Sodium-Glucose Co-transporter-2 Inhibitors and Nephroprotection in Diabetic Patients: More Than a Challenge
Michele Provenzano, Maria Chiara Pelle, Isabella Zaffina, et al.
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 24
The Interplay of Comorbidities in Chronic Heart Failure: Challenges and Solutions
Shashipriya Agress, J. Sheikh, Aida A. Perez Ramos, et al.
Current Cardiology Reviews (2024) Vol. 20, Iss. 3
Closed Access | Times Cited: 3
Bexagliflozin on Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Marília Gobbo, Renan Yuji Ura Sudo, Tanize Louize Milbradt, et al.
Cureus (2025)
Open Access
The efficacy and safety of SGLT2 inhibitors in patients with non-diabetic chronic kidney disease: a systematic review and meta-analysis
Congyuan Ma, Xuanwei Li, Wenlai Li, et al.
International Urology and Nephrology (2023) Vol. 55, Iss. 12, pp. 3167-3174
Closed Access | Times Cited: 8
Renoprotective effect of SGLT-2 inhibitors among type 2 diabetes patients with different baseline kidney function: a multi-center study
Fang‐Ju Lin, Chi‐Chuan Wang, Chien‐Ning Hsu, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 19
Ex vivoconfocal microscopy detects basic patterns of acute and chronic lesions using fresh kidney samples
Jesús Z. Villarreal, Javiera Pérez‐Ánker, Susana Puig, et al.
Clinical Kidney Journal (2023) Vol. 16, Iss. 6, pp. 1005-1013
Open Access | Times Cited: 7
Retrospective analysis of the effect of SGLT-2 inhibitors on renal function in patients with type 2 diabetes in the real world
Rongjing Song, Qiaoyu Hou, Xiuying Zhang, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 2
Nephroprotection by SGLT2i in CKD Patients: May It Be Modulated by Low-Protein Plant-Based Diets?
Adamasco Cupisti, Domenico Giannese, Diego Moriconi, et al.
Frontiers in Medicine (2020) Vol. 7
Open Access | Times Cited: 18
Diet and Proteinuria: State of Art
Paolo Ria, Antonio De Pascalis, Anna Zito, et al.
International Journal of Molecular Sciences (2022) Vol. 24, Iss. 1, pp. 44-44
Open Access | Times Cited: 11
Can SGLT2 inhibitors answer unmet therapeutic needs in chronic kidney disease?
Luca De Nicola, Mario Cozzolino, Simonetta Genovesi, et al.
Journal of Nephrology (2022) Vol. 35, Iss. 6, pp. 1605-1618
Open Access | Times Cited: 9
Role of Estimated Glomerular Filtration Rate in Clinical Research: The Never-Ending Matter
Chiara Abenavoli, Michele Provenzano, Sara H. Ksiazek, et al.
Reviews in Cardiovascular Medicine (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 1
Refractory IgA Nephropathy: A Challenge for Future Nephrologists
Vincenzo Di Leo, Francesca Annese, Federica Papadia, et al.
Medicina (2024) Vol. 60, Iss. 2, pp. 274-274
Open Access | Times Cited: 1
Integrating the new pharmacological standard of care with traditional nutritional interventions in non-dialysis CKD
Luca De Nicola, Adamasco Cupisti, Claudia D’Alessandro, et al.
Journal of Nephrology (2024)
Closed Access | Times Cited: 1
Glomerular Biomechanical Stress and Lipid Mediators during Cellular Changes Leading to Chronic Kidney Disease
Mukut Sharma, Vikas Singh, Ram Sharma, et al.
Biomedicines (2022) Vol. 10, Iss. 2, pp. 407-407
Open Access | Times Cited: 7
Albuminuria and Serum Tumor Necrosis Factor Receptor Levels in Patients with Type 2 Diabetes on SGLT2 Inhibitors: A Prospective Study
Toshiki Otoda, Akiko Sekine, Ryoko Uemoto, et al.
Diabetes Therapy (2023) Vol. 15, Iss. 1, pp. 127-143
Open Access | Times Cited: 3
Emerging Role of Sodium–Glucose Co-Transporter 2 Inhibitors for the Treatment of Chronic Kidney Disease
Rey Isidto, Romina Danguilan, Oscar Naidas, et al.
International Journal of Nephrology and Renovascular Disease (2023) Vol. Volume 16, pp. 43-57
Open Access | Times Cited: 2
Excretion of glucose analogue with SGLT2 affinity predicts response effectiveness to sodium glucose transporter 2 inhibitors in patients with type 2 diabetes mellitus
Barbara Katharina Geist, Helmut Brath, Lucia Zisser, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2023) Vol. 50, Iss. 10, pp. 3034-3041
Open Access | Times Cited: 2
Renal Protection and Safety of Sodium-glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease
Tian‐Biao Zhou, Kaijin Yao, Yina Xie, et al.
Current Pharmaceutical Design (2023) Vol. 29, Iss. 21, pp. 1659-1670
Closed Access | Times Cited: 2
Impact of diet modification on body mass and kidney function in patients with diabetic nephropathy: a pilot study
Małgorzata Kaczkan, Sylwia Czaja-Stolc, Małgorzata Sikorska-Wiśniewska, et al.
Acta Biochimica Polonica (2023)
Open Access | Times Cited: 2
Double Duty: SGLT2 Inhibitors as Cardioprotective and Anticancer Allies
Linda Piras, Michela Zuccanti, Giacomo Tini, et al.
Hearts (2024) Vol. 5, Iss. 4, pp. 529-546
Open Access
Page 1 - Next Page

Scroll to top